Physician profile
George Abraham
NPI 1730181876
$4,621.28
in general payments reported to CMS, 2019-2025
26 companies · $467 in 2025
The $467 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190 · 2020: $205 · 2021: $2,682 · 2022: $402 · 2023: $215 · 2024: $461 · 2025: $467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,142.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,336.67 | 2019-2022 | |
| Abbvie INC. | $510.39 | 2020-2025 | Linzess, Viberzi |
| Astrazeneca Pharmaceuticals LP | $204.30 | 2021-2024 | |
| Gilead Sciences, INC. | $159.83 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $149.20 | 2019-2024 | Eliquis |
| Novartis Pharmaceuticals Corporation | $145.08 | 2019-2022 | |
| Viiv Healthcare Company | $141.69 | 2019-2023 | Dovato |
| Inspire Medical Systems, INC. | $127.52 | 2024-2025 | Inspire |
| Astellas Pharma US INC | $123.56 | 2022-2024 | Myrbetriq, Veozah |
| Nestle Healthcare Nutrition INC. | $123.23 | 2021-2022 | |
| Pfizer INC. | $104.77 | 2019-2025 | |
| Allergan, INC. | $81.44 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $81.15 | 2020-2021 | |
| Abiomed | $49.89 | 2025 | |
| Insmed, INC. | $46.09 | 2024-2025 | Brinsupri, Arikayce |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $30.93 | 2024 | Cologuard Collection Kit |
| Lexicon Pharmaceuticals, INC. | $29.78 | 2024 | Inpefa |
| Novo Nordisk INC | $25.00 | 2022 | |
| Dexcom, INC. | $24.88 | 2021 | |
| Braintree Laboratories, INC. | $23.88 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $22.71 | 2022 | |
| Amgen INC. | $21.74 | 2019 | |
| Janssen Biotech, INC. | $16.93 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.59 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.41 | 2020 | |
| Genentech USA, INC. | $11.62 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.